グループAおよびC髄膜炎菌多糖体ワクチンの第III相臨床試験
2~6歳の健康な小児を対象としたグループAおよびC髄膜炎菌多糖体ワクチンの無作為化二重盲検対照非劣性第III相試験
This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.
調査の概要
状態
条件
詳細な説明
This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Yunnan
-
Kunming、Yunnan、中国
- Yunnan Center for Disease Control and Prevention
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
-
The First stage study (An early safety assessment study):
-
18-50 years group:
-
Inclusion Criteria:
- Healthy adults aged 18 to 50 years.
- Proven legal identity.
- Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
7-17 years group:
-
Inclusion Criteria
- Healthy volunteer aged 7 to 17 years.
- Proven legal identity.
- Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
- Immunization with any vaccine within 30 days.
- Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Women with positive pregnancy test after menarche.
- Any other situations judged by investigators as not suitable for participating in this study.
-
-
2-6 years group:
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
-
The Second stage study (A phase III clinical trial )
-
Inclusion Criteria
- Healthy children aged 2 to 6 years.
- Proven legal identity.
- Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
- Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
- Axillary temperature ≤37.0℃.
-
Exclusion Criteria:
- Contraindications for vaccination.
- History of allergy to vaccines or drugs.
- History of Epidemic Cerebrospinal Meningitis.
- Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
- Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
- They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
- Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
- Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
- Those who developed acute disease or acute attack of chronic disease.
- Surgical removal of spleen or other important organs for any reason.
- History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
- Blood products such as immunoglobulin were received within 30 days before vaccination.
- Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
- Those who participated in other clinical studies.
- Any other situations judged by investigators as not suitable for participating in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Experimental Vaccine
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
One dose of Experimental Group A and C meningococcal polysaccharide vaccine |
|
アクティブコンパレータ:Active Comparator Vaccine
One dose of Control Group A and C meningococcal polysaccharide vaccine |
One dose of Control Group A and C meningococcal polysaccharide vaccine |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Seroconversion rate of Group A meningococcal bactericidal antibody
時間枠:28 days after vaccination
|
Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
|
Seroconversion rate of Group C meningococcal bactericidal antibody
時間枠:28 days after vaccination
|
Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination |
28 days after vaccination
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse reactions/events rate
時間枠:7 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
7 days after vaccination
|
|
Adverse reactions/events rate
時間枠:28 days after vaccination
|
Occurence of adverse reactions/events after vaccination |
28 days after vaccination
|
|
Serious adverse events
時間枠:6 months after the second vaccination
|
Occurence of Serious adverse events after vaccination |
6 months after the second vaccination
|
|
GMT of Group A meningococcal bactericidal antibody
時間枠:28 days after the second vaccination
|
GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
|
GMT of Group C meningococcal bactericidal antibody
時間枠:28 days after the second vaccination
|
GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination |
28 days after the second vaccination
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
GMT of IgG antibody against Hepatitis A
時間枠:28 days after the second vaccination
|
GMT of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
|
Seropositive rate of IgG antibody against Hepatitis A
時間枠:28 days after the second vaccination
|
Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination |
28 days after the second vaccination
|
協力者と研究者
捜査官
- 主任研究者:Yan Zheng, Mater、Yunnan Center for Disease Control and Prevention
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。